抗坏血酸、糖皮质激素与硫胺素联合治疗对脓毒性休克器官损伤的影响:ACTS随机临床试验
ACTS多中心随机双盲试验纳入205例脓毒性休克成人患者,比较抗坏血酸1500 mg、氢化可的松50 mg与硫胺素100 mg每6小时静脉给药共4天与安慰剂。主要终点72小时SOFA评分变化无统计学显著交互(干预组从9.1降至4.4,变化-4.7分 vs 安慰剂组从9.2降至5.1,变化-4.1分;校正平均差-0.8,95%CI -1.7至0.2;P=0.12)。肾衰竭发生率(31.7% vs 27.3%;校正风险差0.03,95%CI -0.1至0.2;P=0.58)与30天死亡率(34.7% vs 29.3%;HR 1.3,95%CI 0.8-2.2;P=0.26)均无统计学显著差异。作者结论认为该数据不支持对脓毒性休克患者常规使用此联合治疗。
要点
- 脓毒性休克成人患者中,抗坏血酸1500 mg+氢化可的松50 mg+硫胺素100 mg每6小时静脉给药共4天,72小时SOFA评分变化与安慰剂无统计学显著差异(校正平均差-0.8,95%CI -1.7至0.2;P=0.12)。
- 30天死亡率干预组34.7% vs 安慰剂组29.3%,无统计学显著差异(HR 1.3,95%CI 0.8-2.2;P=0.26)。
- 肾衰竭发生率干预组31.7% vs 安慰剂组27.3%,无统计学显著差异(校正风险差0.03,95%CI -0.1至0.2;P=0.58)。
- 常见严重不良事件为高血糖(干预组12例 vs 安慰剂组7例)、高钠血症(11例 vs 7例)和新发医院获得性感染(13例 vs 12例)。
- 作者结论:这些数据不支持对脓毒性休克患者常规使用该联合治疗。
适用人群与场景
- 成人脓毒性休克患者,纳入于美国14个中心,2018年2月9日至2019年10月27日入组,随访至2019年11月26日。
- 分析纳入至少接受1剂研究药物的患者:干预组101例,安慰剂组99例。
处置流程与药物剂量
- 干预组:静脉给予抗坏血酸1500 mg、氢化可的松50 mg与硫胺素100 mg,每6小时一次,共4天。
- 对照组:给予匹配体积的安慰剂,在相同时间点给药。
研究设计与关键结果
- 随机、盲法、多中心临床试验,205例患者随机(干预组103例,安慰剂组102例),200例接受至少1剂研究药物并完成试验纳入分析(干预组101例,安慰剂组99例);平均年龄68岁(SD 15),女性90例(44%)。
- 主要终点72小时SOFA评分变化:干预组从9.1降至4.4(变化-4.7分)vs 安慰剂组从9.2降至5.1(变化-4.1分);校正平均差-0.8(95%CI -1.7至0.2;P=0.12 for interaction),无统计学显著交互。
- 肾衰竭发生率:干预组31.7% vs 安慰剂组27.3%;校正风险差0.03(95%CI -0.1至0.2;P=0.58),无统计学显著差异。
- 30天死亡率:干预组34.7% vs 安慰剂组29.3%;HR 1.3(95%CI 0.8-2.2;P=0.26),无统计学显著差异。
- 常见严重不良事件:高血糖(干预组12例 vs 安慰剂组7例)、高钠血症(干预组11例 vs 安慰剂组7例)、新发医院获得性感染(干预组13例 vs 安慰剂组12例)。
证据类型、等级与局限
- 证据类型:随机、盲法、多中心临床试验。
- 试验注册:ClinicalTrials.gov Identifier: NCT03389555。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为,这些数据不支持对脓毒性休克患者常规使用抗坏血酸、糖皮质激素与硫胺素联合治疗。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: The combination of ascorbic acid, corticosteroids, and thiamine has been identified as a potential therapy for septic shock.
OBJECTIVE: To determine whether the combination of ascorbic acid, corticosteroids, and thiamine attenuates organ injury in patients with septic shock.
DESIGN, SETTING, AND PARTICIPANTS: Randomized, blinded, multicenter clinical trial of ascorbic acid, corticosteroids, and thiamine vs placebo for adult patients with septic shock. Two hundred five patients were enrolled between February 9, 2018, and October 27, 2019, at 14 centers in the United States. Follow-up continued until November 26, 2019.
INTERVENTIONS: Patients were randomly assigned to receive parenteral ascorbic acid (1500 mg), hydrocortisone (50 mg), and thiamine (100 mg) every 6 hours for 4 days (n = 103) or placebo in matching volumes at the same time points (n = 102).
MAIN OUTCOMES AND MEASURES: The primary outcome was change in the Sequential Organ Failure Assessment (SOFA) score (range, 0-24; 0 = best) between enrollment and 72 hours. Key secondary outcomes included kidney failure and 30-day mortality. Patients who received at least 1 dose of study drug were included in analyses.
RESULTS: Among 205 randomized patients (mean age, 68 [SD, 15] years; 90 [44%] women), 200 (98%) received at least 1 dose of study drug, completed the trial, and were included in the analyses (101 with intervention and 99 with placebo group). Overall, there was no statistically significant interaction between time and treatment group with regard to SOFA score over the 72 hours after enrollment (mean SOFA score change from 9.1 to 4.4 [-4.7] points with intervention vs 9.2 to 5.1 [-4.1] points with placebo; adjusted mean difference, -0.8; 95% CI, -1.7 to 0.2; P = .12 for interaction). There was no statistically significant difference in the incidence of kidney failure (31.7% with intervention vs 27.3% with placebo; adjusted risk difference, 0.03; 95% CI, -0.1 to 0.2; P = .58) or in 30-day mortality (34.7% vs 29.3%, respectively; hazard ratio, 1.3; 95% CI, 0.8-2.2; P = .26). The most common serious adverse events were hyperglycemia (12 patients with intervention and 7 patients with placebo), hypernatremia (11 and 7 patients, respectively), and new hospital-acquired infection (13 and 12 patients, respectively).
CONCLUSIONS AND RELEVANCE: In patients with septic shock, the combination of ascorbic acid, corticosteroids, and thiamine, compared with placebo, did not result in a statistically significant reduction in SOFA score during the first 72 hours after enrollment. These data do not support routine use of this combination therapy for patients with septic shock.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03389555.
参考来源
- Moskowitz A, Huang DT, Hou PC, et al. Effect of Ascorbic Acid, Corticosteroids, and Thiamine on Organ Injury in Septic Shock: The ACTS Randomized Clinical Trial. JAMA. 2020. PMID: 32809003. doi:10.1001/jama.2020.11946
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。